Longevity

ChromaDex (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way people age, is providing selected preliminary fourth quarter and full year 2017 results. As quoted in the press release: Based on preliminary unaudited information, ChromaDex expects to report net revenues for the fourth quarter of 2017 of approximately $7.5 million, …

ChromaDex (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way people age, is providing selected preliminary fourth quarter and full year 2017 results.

As quoted in the press release:

Based on preliminary unaudited information, ChromaDex expects to report net revenues for the fourth quarter of 2017 of approximately $7.5 million, up 69% compared to $4.5 million from continuing operations in the fourth quarter of 2016. The increase in fourth quarter revenues was driven by growth in sales of TRU NIAGEN®. For the full year 2017, net revenues are expected to be approximately $21.2 million from continuing operations, down 2% compared to $21.7 million in 2016 as the Company shifted to an integrated global, consumer facing nutraceutical company.

Click here to read the full press release.

MARKETS

Markets
TSX18861.36-217.28
TSXV617.26-9.08
DOW30775.43-253.88
S&P 5003785.38-33.45
NASD11028.74-149.16
ASX6568.10-132.10

COMMODITIES

Commodities
Gold1803.13-3.74
Silver20.06-0.19
Copper3.65-0.06
Palladium1929.64+7.64
Platinum898.36+1.36
Oil105.760.00
Heating Oil3.85+0.02
Natural Gas5.71+0.28

DOWNLOAD FREE REPORTS

×